



INTERNATIONAL APPLICATION PUBLISHED 1

(51) International Patent Classification ⁶ :	A61L 25/00, 27/00, A61K 35/32	A1	(11) International Publication Number: WO 96/04026
(43) International Publication Date: 15 February 1996 (15.02.96)			

(21) International Application Number: PCT/US95/09938	(22) International Filing Date: 4 August 1995 (04.08.95)	(30) Priority Data: 286,273 5 August 1994 (05.08.94) US	(81) Designated States: European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(71) Applicant: CHILDREN'S MEDICAL CENTER CORPORATION [US/US]; 55 Shattuck Street, Boston, MA 02115 (US). (72) Inventors: ATALA, Anthony; 74 Westerly Road, Weston, MA 02193 (US). ASHKAR, Samy; Apartment 510, 12 Stoneholm Street, Boston, MA 02155 (US). (74) Agent: PABST, Parea, L.; Arnall Golden & Gregory, 2800 One Atlantic Center, 1201 West Peachtree Street, Atlanta, GA 30309-3450 (US).			

(54) Title: INJECTABLE NON-IMMUNOGENIC CARTILAGE AND BONE PREPARATION

(57) Abstract

Ground bone or cartilage particles are demineralized by extraction with a low ionic strength buffer such as 20 mM HEPES containing a chelating agent and protease inhibitors, then extracted with an acidic solution such as 0.3 M citric acid, pH 4.0, containing protease inhibitors. The extracted material generally contains less than 2 % by weight phosphate and less than 100 mM calcium. The phosphate content can be further reduced by treatment of the matrix with acid phosphatase, which removes residual organic phosphate. The material is useful in a method of treatment of vesicoureteral reflux and other disorders where a bulking agent is effective in correcting the defect.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**INJECTABLE NON-IMMUNOGENIC CARTILAGE
AND BONE PREPARATION**

Background of the Invention

The present invention is generally in the
5 area of medical treatments, and specifically
relates to an method for making a non-immunogenic
cartilage and bone preparation and use thereof as a
bulking agent.

Vesicoureteral reflux is a condition
10 wherein there is an abnormal development of the
ureteral bud as it enters the bladder during
embryologic development. The shortened course of
the ureter through the bladder musculature
decreases the ureteral resistance and allows for
15 urine to reflux from the bladder reservoir back up
into the ureter and into the kidney. With this
condition, bacteria which may occasionally be
present in the bladder through retrograde urethral
transport, can reach the kidneys and cause
20 recurrent pyelonephritis. In addition, the
constant back pressure of the urine into the
calyces and renal pyramids results in mechanical
damage to the renal parenchyma. If untreated,
urinary vesicoureteral reflux can cause loss of
25 renal parenchyma, and in some instances, renal
failure, as reviewed by Atala and Casale,
Infections in Urology 39-43 (March/April 1990). In
1960, 70% of the patients with renal failure were
described as having vesicoureteral reflux as the
30 primary etiology. With the advent of new
diagnostic and treatment modalities, patients with
vesicoureteral reflux now account for less than 1%
of the renal failure population.

The initial management of vesicoureteral
35 reflux usually consists of suppressive antibiotics
in anticipation of spontaneous resolution, as
described by Atala, et al., "Sonography with

sonicated albumin in the detection of vesicoureteral reflux" J. Urol. 150:756-758 (1993).

Depending on the severity of reflux, 20 to 60 percent of patients may ultimately undergo surgical treatment, as reported by Klagsbrun, M. "Large scale preparation of chondrocytes" Methods in Enzymology 58:560 (1979); O'Donnell and Puri, "Treatment of vesicoureteric reflux by endoscopic injection of Teflon" Brit. Med. J. 289: 7 (1984).

10 Although open surgical procedures for the correction of reflux have excellent results in the hands of experienced surgeons, it is associated with a well recognized morbidity, including pain and immobilization of a lower abdominal incision, 15 bladder spasms, hematuria, and post-operative voiding frequency in some children.

The endoscopic treatment of vesicoureteral reflux was first introduced in 1981 when Polytetrafluoroethylene (Teflon) was injected 20 in the subureteral region of a patient, as reported by Matouschek, E.: Die Behandlung des vesikorenalen Refluxes durch transueterale Einspritzung von polytetrafluoroethylenepaste. Urologe, 20:263 (1981). In an effort to avoid open surgical 25 intervention, widespread interest in the endoscopic treatment of reflux was initiated by O'Donnell and Puri's clinical experience with Polytetrafluoroethylene paste in 1984, (Atala and Casale "Management of primary vesicoureteral 30 reflux" Infections in Urol. 2:39 (1990)). Soon thereafter, a controversy regarding the use of polytetrafluoroethylene paste ensued. Particle migration to distant organs raised concerns 35 regarding the use of polytetrafluoroethylene paste, as reported by Malizia, et al., "Migration and granulomatous reaction after periurethral injection of polyef (polytetrafluoroethylene)"

-3-

JAMA, 251:3277 (1984); Claes, et al., "Pulmonary migration following periurethral polytetrafluoroethylene injection for urinary incontinence" J. Urol. 142:821 (1989); Vorstman, et 5 al., "Polytetrafluoroethylene injection for urinary incontinence in children" J. Urol. 133:248 (1985); Mittleman, et al., "Pulmonary polytetrafluoroethylene granulomas following periurethral polytetrafluoroethylene injection for 10 urinary incontinence" Arch. Path. Lab. Med. 107:611 (1983); Ferro, et al., "Periurethral granuloma: Unusual complications of Teflon periurethral injection" Urology 31:422 (1988); Rames, et al., "Migration of polystef paste to the 15 lung and brain following intravesical injection for the correction of reflux" Ped. Surg. Int. 6:239 (1991).

Bovine dermal collagen preparations have been used to treat reflux endoscopically, as 20 reported by Leonard, et al., "Endoscopic injection of glutaraldehyde cross-linked bovine dermal collagen for correction of vesicoureteral reflux" J. Urol. 145:115 (1991). However, only 58.5% of the patients were cured at one year follow-up. The 25 collagen implant volume decreases with time, which results in a high percentage of recurrence of reflux. The high rate of retreatment necessary due to implant volume loss has limited the usefulness of collagen, as discussed in "Medical versus 30 surgical treatment of primary vesicoureteral reflux: a prospective international reflux study in children" Report of the International Reflux Study Committee. J. Urol. 125:277 (1981). The ideal implant material should be non-migratory, non- 35 antigenic, able to be delivered endoscopically, and should conserve its volume.

A paste consisting of textured microparticles of silicone, suspended in a hydrogel, has been injected subureterally to correct reflux with an initial success rate of 91%, 5 as reported by Buckley, et al., "Endoscopic correction of vesicoureteric reflux with injectable microparticulate silicone" Abstract 573 presented at 87th Annual Meeting, AUA, May 10-14, 1993, Washington DC. Although problems have been 10 encountered with the silicone gel-filled prostheses which have the potential to rupture or leak, the solid silicone prostheses have been mostly problem-free. Recently however, concerns have also been raised regarding the non-gel-filled prostheses. 15 Barrett et al. "Particle shedding and migration from silicone genitourinary prosthetic devices" J. Urol. 146:319-322 (1991), showed silicone particles from 18 of 25 urologic periprosthetic specimens, and in all lymph nodes examined. Foreign body 20 granulomas were identified in 29 specimens. Lymphadenopathy and lymphadenitis have occurred after silicone prosthesis implantation (Paplanus and Payne "Axillary lymphadenopathy 17 years after digital silicone implants: study with x-ray 25 microanalysis" J. Hand. Surg. 13:399 (1988); Endo, et al., "Silicone and rheumatic diseases" Sem. Arth. Rheum. 17:112 (1987)). Silicone particles have been found in the enlarged nodes of patients 30 with malignant lymphoma (Digby "Malignant lymphoma with intranodal silicone rubber particles following metacarpophalangeal joint replacements" Hand 14:326 (1982); Benjamin, et al., "Silicone lymphadenopathy: a report of two cases, one with concomitant malignant lymphoma" Diagn. Histopath. 5:133 35 (1982)). The autoimmune disorder human adjuvant disease, is associated with silicone implantation (Sergott, et al., "Human adjuvant disease possible

autoimmune disease after silicone implantation: a review of the literature, case studies, and speculation for the future" Plast. Reconstr. Surg. 78:104 (1986)). Long-term longitudinal studies of 5 patients with silicone prostheses are needed to define the associated risk.

Other materials for the endoscopic treatment of reflux, including a detachable balloon system (Atala et al., "Endoscopic treatment of 10 vesicoureteral reflux with a self-detachable balloon system", J. Urol. 148:724 (1992)) and Bioglass (Walker, et al., "Injectable bioglass as a potential substitute for injectable 15 polytetrafluoroethylene" J. Urol. 148:645 (1992)) are currently under investigation and have not been used in a clinical setting.

Laparoscopic correction of reflux has been attempted in both an animal model (Atala, et al., "Laparoscopic correction of vesicoureteral 20 reflux" J. Urol. 150:748-751 (1993)) and humans (Atala, "Laparoscopic treatment of vesicoureteral reflux" Dial Ped Urol 14:212 (1993)) and is technically feasible. However, at least two 25 surgeons with laparoscopic expertise are needed, the length of the procedure is longer than with open surgery, and the cost is higher due to both increased operative time and the expense of the disposable laparoscopic equipment.

The advantages of the endoscopic 30 treatment for reflux cannot be overlooked. The method is simple, can be completed in less than 15 minutes as an outpatient procedure, has a low morbidity and a success rate of more than 85 percent, as reported by Giss, et al., "Multicenter 35 survey of endoscopic treatment of vesicoureteral reflux in children" Eur. Urol. 17:328 (1990). The ideal substance for the endoscopic treatment of

reflux should be injectable, non-antigenic, non-migratory, volume stable, and safe for human use.

Urinary incontinence.

Urinary Incontinence is the most common

5 and the most intractable of all GU maladies.

Urinary incontinence, or the inability to retain urine and not void urine involuntarily, is dependent on the interaction of two sets of muscles. One is the detrusor muscle, a complex of 10 longitudinal fibers forming the external muscular coating of the bladder. The detrusor is activated by parasympathetic nerves. The second muscle is the smooth/striated muscle of the bladder sphincter. The act of voiding requires the

15 sphincter muscle be voluntarily relaxed at the same time that the detrusor muscle of the bladder contracts. As a person ages, his ability to voluntarily control the sphincter muscle is lost in the same way that general muscle tone deteriorates 20 with age. This can also occur when a radical event such as paraplegia "disconnects" the parasympathetic nervous system causing a loss of 25 sphincter control. In different patients, urinary incontinence exhibits different levels of severity and is classified accordingly.

The most common incontinence, particular in the elderly, is urge incontinence. This type of incontinence is characterized by an extremely brief warning following by immediate urination. This 30 type of incontinence is caused by a hyperactive detrusor and is usually treated with "toilet training" or medication. Reflex incontinence, on the other hand, exhibits no warning and is usually the result of an impairment of the parasympathetic 35 nerve system such as a spinal cord injury.

Stress incontinence is most common in elderly women but can be found in women of any age.

It is also commonly seen in pregnant women. This type of incontinence accounts for over half of the total number of cases. It is also found in men but at a lower incidence. Stress incontinence is 5 characterized by urine leaking under conditions of stress such as sneezing, laughing or physical effort. There are five recognized categories of severity of stress incontinence, designated as types as 0, 1, 2a, 2b, and 3. Type 3 is the most 10 severe and requires a diagnosis of intrinsic Sphincter Deficiency or ISD (Contemporary Urology, March 1993). There are many popular treatments including weight loss, exercise, medication and in more extreme cases, surgical intervention. The two 15 most common surgical procedures involve either elevating the bladder neck to counteract leakage or constructing a lining from the patient's own body tissue or a prosthetic material such as PTFE to put pressure on the urethra. Another option is to use 20 prosthetic devices such as artificial sphincters or external devices such as intravaginal balloons or penile clamps. For treatment of type 3 stress incontinence, there has been a recent trend toward 25 injection of Teflon™ or collagen paste around the sphincter muscle in order to "beef up" the area and improve muscle tone. None of the above methods of treatment, however, are very effective for periods in excess of a year.

Overflow incontinence is caused by 30 anatomical obstructions in the bladder or underactive detrusors. It is characterized by a distended bladder which leads to frequent urine leakage. This type of incontinence is treated acutely by catheterization and long-term by drug 35 therapy. Enuresis or bed-wetting is a problem in pediatrics and is controlled by various alarming devices and pads with sensors. Enuresis is not

considered a serious problem unless it lasts beyond the age of four or five. Finally, there is true functional incontinence which occurs in patients with chronic impairment either of mobility or 5 mental function. Such patients are usually treated by the use of diapers, incontinence pads or continuous catheterization (BBI, 1985 Report 7062).

It is therefore an object of the present invention to provide a method and material for 10 treating vesicoureteral reflux which results in a natural and permanent cure to the defect.

It is a further object of the present invention to provide a method and material for treating vesicoureteral reflux which is quick, 15 simple, safe, and relatively non-invasive.

It is another object of the present invention to provide a bulking material which is non-biodegradable, biocompatible, non-migratory, and can be injected.

20 **Summary of the Invention**

A method of treatment of vesicoureteral reflux and incontinence is described wherein a non-immunogenic demineralized bone and cartilage suspension is prepared that can be mixed with 25 polymeric carriers and/or other pharmaceutically acceptable materials for injection. Examples of suitable polymeric carriers include polyvinylpyrrolidone (PAP), hyaluronic acid, fibrin, glue, saline, alginate, and other polymers 30 forming a hydrogel. The resulting suspension is injectable and can be used for correction of a variety of tissue defects and incontinence. For example, it can be injected into the area where reflux is occurring, in an amount effective to 35 provide the required control over the passage of urine.

-9-

In the preferred embodiment, ground bone or cartilage particles are demineralized by extraction with a low ionic strength buffer such as 20 mM HEPES containing a chelating agent and 5 protease inhibitors, then extracted with an acidic solution such as 0.3 M citric acid, pH 4.0, containing protease inhibitors. The extracted material generally contains less than 2% by weight phosphate and less than 100 mM calcium. The 10 phosphate content can be further reduced by treatment of the matrix with acid phosphatase, which removes residual organic phosphate.

Brief Description of the Drawings

Figure 1 is a schematic of the 15 preparation of and injection of a non-immunogenic cartilage and bone suspension into a region for control of vesicoureteral reflux or incontinence.

Detailed Description of the Invention

Source of Cartilage and Bone

20 In the preferred embodiment, cartilage and/or bone is obtained from the diaphyses of the metatarsal bones or articular cartilage. Hyaline cartilage is the most common type of cartilage. Between the diaphysis and the epiphysis of growing 25 long bones, the epiphyseal plate is composed of hyaline cartilage. In adults, hyaline cartilage is located in the articular surfaces of the movable joints.

30 Forty percent of the dry weight of hyaline cartilage consists of collagen embedded in an amorphous intercellular substance.

Bone is a very dense, specialized form of connective tissue. It is a mixture of type I collagen fibrils and solid inorganic matter.

35 Inorganic matter represents about 50% of the dry

-10-

weight of bones. Calcium and phosphorus are especially abundant, although bicarbonate, citrate, magnesium, potassium, and sodium are also found. The calcium and phosphorus form hydroxyapatite 5 crystals.

The method described herein removes most of the inorganic material from the organic material, to leave an organic matrix useful as a bulking agent to correct tissue defects.

10

Preparation of Cartilage and Bone

The cartilage and/or bone is cleaned, ground in a liquid nitrogen cooled mill to a particle size ranging from 80 to 200 microns, and washed four times with ice cold (0 to 4°C) 15 phosphate buffered saline (PAS). 80 g of bone or cartilage particles are demineralized with 500 ml of prechilled (0 to 4°C) 20 mM HEPES buffer, within a pH range of 6 to 8, preferably 7.4, total ionic strength 5.02, containing a calcium chelating agent 20 such as 0.5 M ethylenediaminetetraacetic acid (EDTA) and protease inhibitors, for example, 1 mM phenylmethylsulfonyl fluoride, 5 mM benzamidine, 0.1 mM epsilon-amino caproic acid, 0.1 β -hydroxy 25 mercuribenzoate, 0.1 mM pyrophosphate, 1 mM sodium fluoride, 1 mM sodium orthovanadate, 10 mM levamisole, and 1 μ g/ml pepstatin A (all available from Sigma Chemical Co, St. Louis, MO), for one to seven days, preferably for two days, at a 30 temperature of between 0 and 6°C, preferably at 2°C. The bone particles are then collected by centrifugation, for example in a GSA rotor at 4000 x g for 30 minutes. The pellet is then reextracted in the HEPES buffer and again collected by 35 centrifugation. The centrifuged solids are then extracted with 1 liter of 0.3 M citric acid pH 4.0 containing protease inhibitors, for one week at 2°C. The solids are again harvested by

-11-

centrifugation as described above, and washed three times with 500 ml of 20 mM HEPES pH 7.4 containing 1 M NaCl followed by three washes with 250 ml of 20 mM HEPES pH 7.4. The wet matrix is dried under 5 vacuum and stored at -20°C.

The resulting material is a demineralized particulate organic matrix having a phosphate content of less than 2% (by weight) and a calcium concentration of less than 1 mg calcium per gram of 10 matrix, preferably less than 0.5 mg calcium per gram of matrix. Calcium is determined by atomic absorption spectroscopy. The phosphate content of the matrix can be further reduced by treating the matrix with acid phosphatase (0.1 U/mg matrix) in 15 0.05 M glycine buffer, pH 4.0 for 6 h at 4°C; or bacterial alkaline phosphatase at pH 9.0, or 3 N NaOH at 50°C for 30 minutes. This treatment removes any residual organic phosphates and reduces the total phosphate content to less than 1%, preferably to 20 less than 0.5 %, or less than 20 mg of phosphate per gram of matrix, preferably less than 10 mg of phosphate per gram of matrix. The major remaining constituent of the matrix is collagen type I (type II for cartilage). Other components of the matrix 25 are collagen type IX, proteoglycans, and trace amounts of osteopontin, osteocalcin, osteonectin and bone sialoprotein. This process renders the remaining substrate substantially non-immunogenic.

Polymer Suspensions

30 A suitable material for a suspension of the particles is biocompatible to preclude migration and immunological complications. It should most preferably also be resorbable over a period of three to six months, allowing for a 35 completely natural tissue replacement. Different polymers can be used to create a matrix suspension which is injected into the patient. In the

preferred embodiment, calcium alginate or biocompatible polymers that can form ionic hydrogels which are malleable are used to suspend the matrix. In the preferred embodiment, the 5 hydrogel is produced by cross-linking the anionic salt of alginic acid, a carbohydrate polymer isolated from seaweed, with calcium cations, whose strength increases with either increasing concentrations of calcium ions or alginate. The 10 alginate solution is mixed with the matrix to be implanted to form an alginate suspension. The suspension is then injected directly into a patient prior to hardening of the suspension. The suspension subsequently hardens over a short period 15 of time due to the presence *in vivo* of physiological concentrations of calcium ions to form a hydrogel.

A hydrogel is defined as a substance formed when an organic polymer (natural or 20 synthetic) is cross-linked via covalent, ionic, or hydrogen bonds to create a three-dimensional open-lattice structure which entraps water molecules to form a gel. Examples of materials which can be used to form a hydrogel include polysaccharides 25 such as alginate, polyphosphazenes, and polyacrylates, which are crosslinked ionically, or block copolymers such as Pluronics™ or Tetronics™, polyethylene oxide-polypropylene glycol block copolymers which are crosslinked by temperature or 30 pH, respectively, or light or radiation.

In general, these polymers are at least partially soluble in aqueous solutions, such as water, buffered salt solutions, or aqueous alcohol solutions, that have charged side groups, or a 35 monovalent ionic salt thereof. Examples of polymers with acidic side groups that can be reacted with cations are poly(phosphazenes),

-13-

poly(acrylic acids), poly(methacrylic acids), copolymers of acrylic acid and methacrylic acid, poly(vinyl acetate), and sulfonated polymers, such as sulfonated polystyrene. Copolymers having 5 acidic side groups formed by reaction of acrylic or methacrylic acid and vinyl ether monomers or polymers can also be used. Examples of acidic groups are carboxylic acid groups, sulfonic acid groups, halogenated (preferably fluorinated) 10 alcohol groups, phenolic OH groups, and acidic OH groups.

Examples of polymers with basic side groups that can be reacted with anions are poly(vinyl amines), poly(vinyl pyridine), 15 poly(vinyl imidazole), and some imino substituted polyphosphazenes. The ammonium or quaternary salt of the polymers can also be formed from the backbone nitrogens or pendant imino groups. Examples of basic side groups are amino and imino 20 groups.

Alginate can be ionically cross-linked with divalent cations, in water, at room temperature, to form a hydrogel matrix. Polyphosphazenes are polymers with backbones 25 consisting of nitrogen and phosphorous separated by alternating single and double bonds. Each phosphorous atom is covalently bonded to two side chains ("R"). The repeat unit in polyphosphazenes has the general structure (1):



35 where n is an integer.

The polyphosphazenes suitable for cross-linking have a majority of side chain groups which are acidic and capable of forming salt bridges with

di- or trivalent cations. Examples of preferred acidic side groups are carboxylic acid groups and sulfonic acid groups. Hydrolytically stable polyphosphazenes are formed of monomers having 5 carboxylic acid side groups that are crosslinked by divalent or trivalent cations such as Ca^{2+} or Al^{3+} . Polymers can be synthesized that degrade by hydrolysis by incorporating monomers having imidazole, amino acid ester, or glycerol side 10 groups.

Bioerodible polyphosphazenes have at least two differing types of side chains, acidic side groups capable of forming salt bridges with multivalent cations, and side groups that hydrolyze 15 under *in vivo* conditions, e.g., imidazole groups, amino acid esters, glycerol and glucosyl. The term bioerodible or biodegradable, as used herein, means a polymer that dissolves or degrades within a period that is acceptable in the desired application 20 (usually *in vivo* therapy), once exposed to a physiological solution of pH 6-8 having a temperature of between about 25°C and 38°C. Hydrolysis of the side chain results in erosion of 25 the polymer. Examples of hydrolyzing side chains are unsubstituted and substituted imidizoles and amino acid esters in which the group is bonded to the phosphorous atom through an amino linkage (polyphosphazene polymers in which both R groups are attached in this manner are known as 30 polyaminophosphazenes). For polyimidazolephosphazenes, some of the "R" groups on the polyphosphazene backbone are imidazole rings, attached to phosphorous in the backbone through a ring nitrogen atom. Other "R" groups can 35 be organic residues that do not participate in hydrolysis, such as methyl phenoxy groups or other

-15-

groups shown in the scientific paper of Allcock, et al., Macromolecule 10:824-830 (1977).

Methods for synthesis and the analysis of various types of polyphosphazenes are described by
5 Allcock, H.R.; et al., Inorg. Chem. 11, 2584
(1972); Allcock, et al., Macromolecules 16, 715
(1983); Allcock, et al., Macromolecules 19, 1508
(1986); Allcock, et al., Biomaterials, 19, 500
(1988); Allcock, et al., Macromolecules 21, 1980
10 (1988); Allcock, et al., Inorg. Chem. 21(2), 515-
521 (1982); Allcock, et al., Macromolecules 22, 75
(1989); U.S. Patent Nos. 4,440,921, 4,495,174 and
4,880,622 to Allcock, et al.; U.S. Patent No.
4,946,938 to Magill, et al.; and Grolleman, et al.,
15 J. Controlled Release 3, 143 (1986), the teachings
of which are specifically incorporated herein by
reference.

Methods for the synthesis of the other polymers described above are known to those skilled
20 in the art. See, for example Concise Encyclopedia
of Polymer Science and Polymeric Amines and
Ammonium Salts, E. Goethals, editor (Pergamon
Press, Elmsford, NY 1980). Many polymers, such as
25 poly(acrylic acid) and polyvinylpyrrolidone, are
commercially available.

The water soluble polymer with charged side groups is crosslinked by reacting the polymer with an aqueous solution containing multivalent ions of the opposite charge, either multivalent cations if the polymer has acidic side groups or multivalent anions if the polymer has basic side groups. The preferred cations for cross-linking of the polymers with acidic side groups to form a hydrogel are divalent and trivalent cations such as
30 copper, calcium, aluminum, magnesium, strontium, barium, and tin, although di-, tri- or tetra-
35 functional organic cations such as alkylammonium

-16-

salts, e.g., $R_3N^+ - \backslash / \backslash / \backslash / -^+NR_3$, can also be used. Aqueous solutions of the salts of these cations are added to the polymers to form soft, highly swollen hydrogels and membranes. The higher the 5 concentration of cation, or the higher the valence, the greater the degree of cross-linking of the polymer. Concentrations from as low as 0.005 M have been demonstrated to cross-link the polymer. Higher concentrations are limited by the solubility 10 of the salt.

The preferred anions for cross-linking of the polymers to form a hydrogel are divalent and trivalent anions such as low molecular weight dicarboxylic acids, for example, terephthalic acid, 15 sulfate ions and carbonate ions. Aqueous solutions of the salts of these anions are added to the polymers to form soft, highly swollen hydrogels and membranes, as described with respect to cations.

Other types of polymeric carriers that 20 can be utilized are naturally occurring polymers such as hyaluronic acid and fibrin glue.

Matrix Suspensions

The matrix material can be suspended in an aqueous solution such as phosphate buffered 25 saline or mixed with a polymeric material of the type described above. In the latter case, the matrix and polymer is preferably dissolved in water, saline, buffer or polymeric solution to form a suspension.

Injection of Matrix Suspension

Vesicoureteral reflux is one of the most common congenital defects in children, affecting approximately 1% of the population. Although all 35 patients do not require surgical treatment, it is still one of the most common procedure performed in children. Over 600 ureteral reimplants are performed yearly at Children's Hospital in Boston,

Massachusetts. This translates to an approximately saving of 3600 inpatient hospital days per year at this institution alone, if the endoscopic treatment described herein is used instead of open surgery.

5 As described herein, an injectable biodegradable demineralized organic matrix derived from cartilage and/or bone is useful in the treatment of reflux. In the preferred embodiment, the matrix material is mixed with a polymeric
10 material such as alginate, and the matrix-polymer suspension is injected endoscopically in the sub-ureteral region to correct reflux. In one embodiment, the time to solidification of the polymeric-matrix suspension may be manipulated by
15 varying the concentration of calcium as well as the temperature at which the chondrocytes are added to the alginate. The use of autologous cartilage or bone precludes an immunologic reaction.
Solidification of the alginate impedes its
20 migration until after it is degraded.

The suspension can be injected through a cystoscopic needle, having direct visual access with a cystoscope to the area of interest, such as for the treatment of vesico-ureteral reflux or
25 urinary incontinence. In addition to the use of the chondrocyte-polymer suspension for the treatment of reflux and incontinence, the suspension can also be applied to reconstructive surgery, as well as its application anywhere in the
30 human body where a biocompatible permanent injectable material is necessary, such as for repair of soft or hard tissue defects. The suspension can be injected endoscopically, for example through a laryngoscope for injection into
35 the vocal chords for the treatment of dysphonia, or through a hysteroscope for injection into the fallopian tubes as a method of rendering the

patient infertile, or through a proctoscope, for injection of the substance in the perirectal sphincter area, thereby increasing the resistance in the sphincter area and rendering the patient

5 continent of stool.

The suspension can be injected via a syringe and needle directly into a specific area wherever a bulking agent is desired, i.e., a soft tissue deformity such as that seen with areas of

10 muscle atrophy due to congenital or acquired diseases or secondary to trauma, burns, and the like. An example of this would be the injection of the suspension in the upper torso of a patient with muscular atrophy secondary to nerve damage.

15 The suspension can also be injected as a bulking agent for hard tissue defects, such as bone or cartilage defects, either congenital or acquired disease states, or secondary to trauma, burns, or the like. An example of this would be an injection

20 into the area surrounding the skull where a bony deformity exists secondary to trauma. The injunction in these instances can be made directly into the needed area with the use of a needle and syringe under local or general anesthesia.

25 The suspension could also be injected percutaneously by direct palpation, such as by placing a needle inside the vas deferens and occluding the same with the injected bulking substance, thus rendering the patient infertile.

30 The suspension could also be injected through a catheter or needle with fluoroscopic, sonographic, computed tomography, magnetic resonance imaging or other type of radiologic guidance. This would allow for placement or injection of this substance

35 either by vascular access or percutaneous access to specific organs or other tissue regions in the body, wherever a bulking agent would be required.

Further, this substance could be injected through a laparoscopic or thoracoscope to any intraperitoneal or extraperitoneal or thoracic organ. For example, the suspension could be 5 injected in the region of the gastro-esophageal junction for the correcting of gastroesophageal reflux. This could be performed either with a thoracoscope injecting the substance in the esophageal portion of the gastroesophageal region, 10 or via a laparoscope by injecting the substance in the gastric portion of the gastroesophageal region, or by a combined approach.

The system of injectable non-immunogenic cartilage and bone preparation may also be 15 applicable for the treatment of other medical conditions, such as dysphonia.

The present invention will be further understood by reference to the following non-limiting example. The example demonstrates that 20 the matrix-polymer suspension is injectable, non-migratory, and appears to conserve its volume, and is useful in the endoscopic treatment of vesicoureteral reflux.

25 **Example 1: Non-immunogenic Demineralized Bone as a Potential Treatment for Vesicoureteral Reflux.**

Diaphyses of bovine metatarsal bones were cleaned, ground in a liquid nitrogen cooled mill, and washed with ice cold phosphate buffered saline 30 containing protease inhibitors. The bone particles were demineralized and collected by centrifugation. The matrix was then extracted with 0.3 M citric acid at 2°C. The wet matrix was dried under vacuum and stored at -20°C until used. The process 35 renders the matrix non-immunogenic.

The demineralized substrate was mixed with polyvinylpyrrolidone (PAP), a hydrophilic

-20-

carrier which is a biologically compatible substance. Thirty nude mice were injected with a 500 microliter solution. Each mouse was injected at one site with a solution of demineralized bone 5 substrate with PAP and at a different site with a control (60 injection sites) of PAP alone. Animals were sacrificed at two, four, six, eight and twenty weeks after implantation.

Histologic examination of the injection 10 areas demonstrated a bead of demineralized bone substrate. Examination of the injection sites over increasing periods of time showed that the size of the substrate complex appeared to be uniform and stable. The control sites injected with PAP alone 15 showed full reabsorption with no untoward effects. Histologic analysis of distant organs showed no evidence of bone matrix migration or granuloma formation.

Modifications and variations of the 20 present invention will be obvious to those skilled in the art from the foregoing detailed description. Such modifications and variations are intended to come within the scope of the appended claims.

We claim:

1. A method for correcting a tissue defect comprising administering to a patient in need of treatment thereof a demineralized organic matrix suspension, wherein the organic matrix is prepared by leaching of cartilage or bone to produce an organic material containing less than 2% by weight of phosphate and less than 100 mM calcium, in an amount effective to correct the tissue defect without creation of new tissue.

2. The method of claim 1 wherein the matrix is prepared by grinding bone and/or cartilage to form particles having a diameter of between approximately 80 and 200 microns and leaching out calcium and other divalent ions with a buffered aqueous chelating solution and 1 M salt solution.

3. The method of claim 2 wherein the matrix is prepared by treatment with acid phosphatase to remove phosphate remaining after leaching with aqueous chelating and salt solutions.

4. The method of claim 1 wherein the matrix is suspended in a pharmaceutically acceptable carrier.

5. The method of claim 4 wherein the carrier is selected from the group consisting of buffered aqueous solutions and biocompatible, biodegradable polymer solutions.

6. The method of claim 5 wherein the polymer is crosslinked *in vivo* to form a hydrogel encapsulating the matrix.

7. The method of claim 5 wherein the polymer is selected from the group consisting of polysaccharides, polyphosphazenes, polyacrylates, and polyethylene oxide-polypropylene glycol block copolymers which are crosslinked by temperature or

-22-

pH, polyvinylpyrrolidone, fibrin glue and hyaluronic acid.

8. The method of claim 1 wherein the material is administered to correct vesicoureteral reflux.

9. The method of claim 1 wherein the material is administered to correct incontinence.

10. The method of claim 1 wherein the material is to block tubes and sterilize an individual.

11. A method for isolating an organic matrix from cartilage or bone comprising

obtaining a material from the group consisting of growing bone and cartilage,

leaching the material with an aqueous chelating solution at a temperature less than 6° to 15 °C to yield a de-calcified solid,

extracting the leached solid with an acidic solution containing protease inhibitors at a temperature less than 6°C to 15°C, and

further extracting the extracted leached solid with a salt solution at a temperature of less than 6°C to 15°C to yield a demineralized material having a total phosphate content of less than 2% by weight and less than 100 mM phosphate.

12. The method of claim 11 further comprising

treating the demineralized material with acid phosphatase to decrease the phosphate content of the resulting material to less than 1% by weight.

13. The method of claim 11 wherein the chelating agent is an aqueous solution of EDTA.

14. The method of claim 11 wherein the salt solution is a sodium chloride solution.

15. The method of claim 11 wherein the starting material is cartilage.

-23-

16. The method of claim 11 wherein the starting material is bone.

17. A demineralized organic matrix prepared by the method comprising

obtaining a material from the group consisting of growing bone and cartilage,

leaching the material with an aqueous chelating solution at a temperature less than 6°C to 15°C to yield a de-calcified solid,

extracting the leached solid with an acidic solution containing protease inhibitors at a temperature less than 6°C to 15°C, and

further extracting the extracted leached solid with a salt solution at a temperature of less than 6°C to 15°C to yield a demineralized material having a total phosphate content of less than 2% by weight and less than 100 mM phosphate.

18. The material of claim 17 wherein the method further comprises

treating the demineralized material acid phosphatase to decrease the phosphate content of the resulting material to less than 1% by weight.

19. The material of claim 17 wherein the starting material is cartilage.

20. The material of claim 17 wherein the starting material is bone.

1 / 1




FIG. 1

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

Internal Application No
PCT/US 95/09938A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61L25/00 A61L27/00 A61K35/32

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61L A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB,A,2 175 506 (AMERICAN HOSPITAL SUPPLY CORP) 3 December 1986 see the whole document ---	1,2,4,5
X	US,A,5 092 887 (GENDLER EL) 3 March 1992 see column 4, line 46 - column 7, line 19 ---	1,2,4,5
X	EP,A,0 082 621 (COLLAGEN CORP) 29 June 1983 see the whole document ---	1,4-7
X	EP,A,0 495 284 (OSTEOTECH INC) 22 July 1992 see column 2, line 16 - column 9, line 19 ---	1,2,4-7
X	US,A,5 112 354 (Sires BRYAN S) 12 May 1992 see column 5, line 42 - column 6, line 55 ---	1,2,4,5
		-/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

16 November 1995

Date of mailing of the international search report

12.12.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl.
Fax (+ 31-70) 340-3016

Authorized officer

Sitch, W

INTERNATIONAL SEARCH REPORT

Internat	Application No
PCT/US 95/09938	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,90 10018 (CREATIVE BIOMOLECULES INC) 7 September 1990 see page 1, paragraph 2 - page 17, paragraph 1 see page 20, paragraph 1 - page 22, paragraph 2 see page 27, paragraph 4 - page 28, paragraph 1 ---	1,4-7
X	US,A,4 172 128 (THIELE ERHARD ET AL) 23 October 1979 see column 2, line 3 - column 3, line 58 ---	1,2,4,5
X	DATABASE MEDLINE FILE SERVER STN KARLSRUHE ABSTRACT 81280792, MULLIKEN ET AL 'USE OF DEMINERALIZED ALLOGENEIC BONE IMPLANTS FOR THE CORRECTION OF MAXILLOCRANIOFACIAL DEFORMITIES' & ANN SURG, (1981 SEP) 194 (3) 366-72 see abstract -----	1,4,5

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 95/09938

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 1-10

because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claims 1-10 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. Claims Nos.:

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Internal Application No
PCT/US 95/09938

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
GB-A-2175506	03-12-86	US-A- 4627853		09-12-86
		DE-A- 3617897		04-12-86
		FR-A, B 2582517		05-12-86
		JP-A- 62032965		12-02-87
US-A-5092887	03-03-92	NONE		
EP-A-0082621	29-06-83	US-A- 4430760		14-02-84
		CA-A- 1195051		15-10-85
		JP-C- 1355279		24-12-86
		JP-A- 58105752		23-06-83
		JP-B- 61009059		19-03-86
EP-A-0495284	22-07-92	US-A- 5236456		17-08-93
		JP-A- 4246359		02-09-92
		US-A- 5405390		11-04-95
US-A-5112354	12-05-92	NONE		
WO-A-9010018	07-09-90	US-A- 5011691		30-04-91
		US-A- 4975526		04-12-90
		AT-T- 124051		15-07-95
		AU-B- 628050		10-09-92
		AU-B- 3444989		03-11-89
		AU-B- 618357		19-12-91
		AU-B- 3530589		03-11-89
		AU-B- 627850		03-09-92
		AU-B- 5174790		26-09-90
		DE-D- 69020254		27-07-95
		EP-A- 0372031		13-06-90
		EP-A- 0362367		11-04-90
		EP-A- 0411105		06-02-91
		JP-T- 3504736		17-10-91
		JP-T- 3500655		14-02-91
		JP-T- 3502579		13-06-91
		WO-A- 8909787		19-10-89
		WO-A- 8909788		19-10-89
		US-A- 5171574		15-12-92
		US-A- 5162114		10-11-92
		US-A- 5182365		26-01-93

INTERNATIONAL SEARCH REPORTInternat Application No
PCT/US 95/09938

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9010018		US-A-	5266683	30-11-93
		US-A-	5344654	06-09-94
		US-A-	5324819	28-06-94
		US-A-	5354557	11-10-94
		US-A-	5258494	02-11-93
		CA-A-	2027259	18-04-91
-----	-----	US-A-4172128	23-10-79	NONE
-----	-----			